Biomerix Granted US Patent for Its Proprietary Biomaterial Platform Technology

FREMONT, Calif., Oct. 13 /PRNewswire/ -- Biomerix Corporation today announced that the United States Patent and Trademark Office (USPTO) has granted a patent for its proprietary biomaterial platform technology titled "Reticulated elastomeric matrices, their manufacture and use in implantable devices." The Company's platform technology, the Biomerix Biomaterial™ is a non-resorbable reticulated, polycarbonate polyurethane-urea, consisting of an open-cell, three-dimensional, interconnected tissue scaffold. The novel structure of the biomaterial translates into an ability to support predictable, organized fibrovascular tissue ingrowth and remodeling.

The Biomerix Biomaterial is designed to play a role similar to the body's extracellular matrix (ECM), through the main phases of inflammation, proliferation, and remodeling.  Benefits of the Biomerix Biomaterial extend beyond medical device applications. The material's unique structure and chemistry impart differentiated benefits including high porosity, excellent resilience, long-term durability and superior chemical compatibility over current polymeric materials. It is these advantages that make the Biomerix Biomaterial a compelling alternative for potential industrial and consumer applications.  

"Biomerix secured one of its most important intellectual property assets representing a significant milestone for our company and is the culmination of extensive research and development," stated Kenneth G. Hayes, President and Chief Executive Officer of Biomerix Corporation. "The scope of this technology is far reaching and has the potential to drive technological innovation across a broad spectrum of applications in the medical, industrial, and consumer industries."

The US patent number is 7,803,395.

About Biomerix Corporation

Biomerix Corporation develops and manufactures novel and proprietary materials to meet the needs of medical, industrial, and consumer markets. The Company has successfully developed its first biomaterial platform, the Biomerix Biomaterial™, which is a non-resorbable, polycarbonate polyurethane-urea scaffold that has been shown to support fibrovascular tissue in-growth in a wide range of preclinical studies. The Biomerix Biomaterial has received U.S. FDA clearance for vascular, orthopedic, and soft tissue repair applications.

For more information please call 888.308.3620 or visit www.biomerix.com

SOURCE Biomerix Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED